Type 2 Diabetes is a progressive metabolic disorder characterized by impaired insulin secretion, reduced β-cell function, and systemic insulin resistance. β-Stem is designed to address these underlying pathological mechanisms rather than providing only glycemic control.

Therapeutic Rationale

Umbilical cord–derived MSCs possess regenerative, immunomodulatory, and metabolic regulatory properties that make them suitable candidates for diabetes-related tissue repair and functional restoration.

• • Support of pancreatic β-cell repair and functional recovery
• • Reduction of chronic inflammation associated with insulin resistance
• • Improvement of insulin sensitivity in peripheral tissues
• • Modulation of metabolic and immune signaling pathways

Potential Benefits

β-Stem is being developed to deliver durable metabolic benefits for patients with Type 2 Diabetes, including:

• • Improved glycemic control and insulin responsiveness
• • Preservation of endogenous pancreatic function
• • Reduction in diabetes-related complications
• • Enhanced metabolic stability and quality of life

Development Focus

β-Stem is part of RCT’s metabolic disease research pipeline. Ongoing development efforts focus on evaluating safety, biological activity, and translational potential to support future clinical studies in Type 2 Diabetes.